This inventor holds 136 USPTO granted patents and 40 published patent applications, plus 3 CIPO patents and 64 EPO patents, primarily in HIV and Hepatitis C Inhibitors (CPC class A61K45-06). Top assignees: Bristol-Myers Squibb Compnay, Viiv Healthcare UK (No.5) Limited, Bristol-Myers Company. Active years: 1989-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- New Haven, CT (US) (1989)
- Meriden, CT (US) (1990 - 1991)
- Wallingford, CO (US) (2016)
- Wallingford, CT (US) (1993 - 2021)
- Branford, CT (US) (2021 - 2022)
Company Filing History:
106 out of 3,745 
18 out of 45 
5 out of 637 
Years Active: 1989-2022
Areas of Expertise:
John F Kadow: A Prolific Innovator in the Field of HIV Treatment
Introduction:
In the arena of pharmaceutical innovations, John F Kadow has made significant contributions to the field of human immunodeficiency virus (HIV) treatment. Hailing from Wallingford, CT, Kadow has an impressive track record of 133 patents under his belt. In this article, we will delve into his latest patents, career highlights, and notable collaborations.
Latest Patents:
Two of Kadow's recent patent inventions demonstrate his dedication to combating HIV infection. The first patent titled "4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication" outlines the development of compounds that can effectively inhibit the replication of HIV. These compounds, along with their pharmaceutically acceptable salts, offer potential in the treatment of the virus.
The second patent, "Salts of prodrugs of piperazine and substituted piperidine antiviral agents," focuses on the creation of prodrug compounds for HIV treatment. These prodrugs, categorized as Compound I, are instrumental in combatting the progression of the virus within the body. Moreover, Kadow's invention provides intermediate Compound II, which plays a key role in manufacturing the prodrug compounds.
Career Highlights:
Kadow's exceptional contributions to the pharmaceutical industry have predominantly taken place in renowned companies. He has played a pivotal role in the research and development of HIV treatments both at Bristol-Myers Squibb Company and Viiv Healthcare UK Limited. Through his expertise and dedication, Kadow has consistently demonstrated his commitment to finding novel solutions and advancements in HIV treatment.
Collaborations:
In his endeavors, Kadow has had the privilege of collaborating with esteemed colleagues in the field. Two of his notable coworkers include Tao Wang and Zhongxing Zhang. Their collective efforts, combined with Kadow's specialized knowledge, have undoubtedly contributed to the success of the innovative patents he has obtained.
Conclusion:
John F Kadow's accomplishments in the field of HIV treatment and research are remarkable. With 133 patents to his name, his unwavering dedication to finding improved solutions for combating HIV showcases his invaluable expertise. Furthermore, his contributions to companies like Bristol-Myers Squibb and Viiv Healthcare have undoubtedly had a significant impact on the development of novel pharmaceutical treatments. Kadow's patents and collaborations reflect his commitment to making substantial advancements in the field and leaving a lasting positive impact on those affected by HIV.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile